{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T06:30:17Z","timestamp":1787725817792,"version":"build-2784847793"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T00:00:00Z","timestamp":1760486400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81872102,81802569"],"award-info":[{"award-number":["81872102,81802569"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Biol Toxicol"],"DOI":"10.1007\/s10565-025-10091-x","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T08:33:58Z","timestamp":1760517238000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Ginsenoside Rh2 targets SIRT1-mediated deacetylation to modulate ER\u03b1\/AR balance and overcome endocrine therapy resistance in prostate cancer using 3D organoid models"],"prefix":"10.1007","volume":"41","author":[{"given":"Xinan","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueying","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zezhong","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenyang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimeng","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengbo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haowen","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,15]]},"reference":[{"key":"10091_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2021.107932","volume":"228","author":"M Adamaki","year":"2021","unstructured":"Adamaki M, Zoumpourlis V. Prostate cancer biomarkers: from diagnosis to prognosis and precision-guided therapeutics. Pharmacol Ther. 2021;107932. https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107932.","journal-title":"Pharmacol Ther"},{"issue":"18","key":"10091_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15184653","volume":"15","author":"S Belluti","year":"2023","unstructured":"Belluti S, Imbriano C, Casarini L. Nuclear estrogen receptors in prostate cancer: from genes to function. Cancers. 2023;4653. https:\/\/doi.org\/10.3390\/cancers15184653.","journal-title":"Cancers"},{"key":"10091_CR3","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s00280-023-04583-y","volume":"92","author":"M Ben-Eltriki","year":"2023","unstructured":"Ben-Eltriki M, Shankar G, Tomlinson Guns ES, Deb S. Pharmacokinetics and pharmacodynamics of Rh2 and aPPD ginsenosides in prostate cancer: a drug interaction perspective. Cancer Chemother Pharmacol. 2023;92:419\u201337. https:\/\/doi.org\/10.1007\/s00280-023-04583-y.","journal-title":"Cancer Chemother Pharmacol"},{"key":"10091_CR4","doi-asserted-by":"publisher","unstructured":"Berruti A, Dalla Volta A. Resistance to Hormonal Therapy in Prostate Cancer [Internet]. Handbook of Experimental Pharmacology. Cham: Springer International Publishing; 2017 [cited 2025 Jul 29]. p. 181\u201394. Available from: https:\/\/doi.org\/10.1007\/164_2017_21","DOI":"10.1007\/164_2017_21"},{"key":"10091_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100962","volume":"68","author":"M Cai","year":"2023","unstructured":"Cai M, Song X-L, Li X-A, Chen M, Guo J, Yang D-H, et al. Current therapy and drug resistance in metastatic castration-resistant prostate cancer. Drug Resist Updat. 2023;100962. https:\/\/doi.org\/10.1016\/j.drup.2023.100962.","journal-title":"Drug Resist Updat"},{"key":"10091_CR6","doi-asserted-by":"publisher","DOI":"10.1126\/science.abn0478","author":"JM Chan","year":"2022","unstructured":"Chan JM, Zaidi S, Love JR, Zhao JL, Setty M, Wadosky KM, et al. Lineage plasticity in prostate cancer depends on JAK\/STAT inflammatory signaling. Science. 2022. https:\/\/doi.org\/10.1126\/science.abn0478.","journal-title":"Science"},{"key":"10091_CR7","doi-asserted-by":"publisher","first-page":"427","DOI":"10.2119\/molmed.2014.00105","volume":"20","author":"P Christoforou","year":"2014","unstructured":"Christoforou P, Christopoulos PF, Koutsilieris M. The role of estrogen receptor \u03b2 in prostate cancer. Mol Med. 2014;20:427\u201334. https:\/\/doi.org\/10.2119\/molmed.2014.00105.","journal-title":"Mol Med"},{"key":"10091_CR8","doi-asserted-by":"publisher","unstructured":"Czernin J, Current K, Mona CE, Nyiranshuti L, Hikmat F, Radu CG, et al. Immune-checkpoint blockade enhances 225Ac-PSMA617 efficacy in a mouse model of prostate cancer. J Nucl Med. 2020(2). https:\/\/doi.org\/10.2967\/jnumed.120.246041.","DOI":"10.2967\/jnumed.120.246041"},{"key":"10091_CR9","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab002","author":"K Desai","year":"2021","unstructured":"Desai K, McManus JM, Sharifi N, The Endocrine Society. Hormonal therapy for prostate cancer. Endocr Rev. 2021. https:\/\/doi.org\/10.1210\/endrev\/bnab002.","journal-title":"Endocr Rev"},{"key":"10091_CR10","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-023-01642-7","author":"SE Di Carlo","year":"2023","unstructured":"Di Carlo SE, Raffenne J, Varet H, Ode A, Granados DC, Stein M, et al. Depletion of slow-cycling PDGFR\u03b1+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis. Nat Immunol. 2023. https:\/\/doi.org\/10.1038\/s41590-023-01642-7.","journal-title":"Nat Immunol"},{"key":"10091_CR11","doi-asserted-by":"publisher","unstructured":"DiNicolantonio JJ, McCarty MF, Assanga SI, Lujan LL, O\u2019Keefe JH. Ferulic acid and berberine, via Sirt1 and AMPK, may act as cell cleansing promoters of healthy longevity [Internet]. Open Heart. BMJ; 2022 [cited 2025 Jul 29]. p. e001801. Available from: https:\/\/doi.org\/10.1136\/openhrt-2021-001801","DOI":"10.1136\/openhrt-2021-001801"},{"key":"10091_CR12","doi-asserted-by":"publisher","unstructured":"Feng Y, Deng Y, Tang Z, Cai S, Li J, Liu R, et al. Prognostic implication of heterogeneity and trajectory progression induced by enzalutamide in prostate cancer [Internet]. Front. Endocrinol. Frontiers Media SA; 2023 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.3389\/fendo.2023.1148898","DOI":"10.3389\/fendo.2023.1148898"},{"key":"10091_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctarc.2023.100739","volume":"36","author":"A Heydari","year":"2023","unstructured":"Heydari A, Shakiba B, Moradi A, Soofian SE, Abian N, Heidari K, et al. Pharmaceutical industry funding and chemotherapy trials for prostate cancer: a systematic review. Cancer Treat Res Commun. 2023;100739. https:\/\/doi.org\/10.1016\/j.ctarc.2023.100739.","journal-title":"Cancer Treat Res Commun"},{"key":"10091_CR14","doi-asserted-by":"publisher","DOI":"10.1002\/mc.23412","author":"S Huang","year":"2022","unstructured":"Huang S, Rivas P, Yang X, Lai Z, Chen Y, Schadler KL, et al. SIRT1 inhibition\u2010induced senescence as a strategy to prevent prostate cancer progression. Mol Carcinog. 2022. https:\/\/doi.org\/10.1002\/mc.23412.","journal-title":"Mol Carcinog"},{"key":"10091_CR15","doi-asserted-by":"publisher","unstructured":"Kim SB, Song IH, Kim SY, Ko HY, Kil HS, Chi DY, et al. Preclinical Evaluation of a Companion Diagnostic Radiopharmaceutical, [18F]PSMA-1007, in a Subcutaneous Prostate Cancer Xenograft Mouse Model [Internet]. Mol. Pharmaceutics. American Chemical Society (ACS); 2022 [cited 2025 Jul 29]. p. 1050\u201360. Available from: https:\/\/doi.org\/10.1021\/acs.molpharmaceut.2c00788","DOI":"10.1021\/acs.molpharmaceut.2c00788"},{"key":"10091_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-023-02479-5","author":"S Kumar","year":"2023","unstructured":"Kumar S, Swamy N, Tuli HS, Rani S, Garg A, Mishra D, et al. Myricetin: a potential plant-derived anticancer bioactive compound\u2014an updated overview. Naunyn-Schmiedebergs Arch Pharmacol. 2023. https:\/\/doi.org\/10.1007\/s00210-023-02479-5.","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"issue":"17","key":"10091_CR17","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175602","volume":"27","author":"H Li","year":"2022","unstructured":"Li H, Han C, Chen C, Han G, Li Y, MDPI AG. (20S) ginsenoside rh2-activated, distinct apoptosis pathways in highly and poorly differentiated human esophageal cancer cells. Molecules. 2022a;5602. https:\/\/doi.org\/10.3390\/molecules27175602.","journal-title":"Molecules"},{"key":"10091_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2022.109217","volume":"248","author":"Q Li","year":"2023","unstructured":"Li Q, He J, Li S, Tian C, Yang J, Yuan H, et al. The combination of gemcitabine and ginsenoside Rh2 enhances the immune function of dendritic cells against pancreatic cancer via the CARD9-BCL10-MALT1 \/ NF-\u03baB pathway. Clin Immunol. 2023;109217. https:\/\/doi.org\/10.1016\/j.clim.2022.109217.","journal-title":"Clin Immunol"},{"issue":"17","key":"10091_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/molecules27175594","volume":"27","author":"W Li","year":"2022","unstructured":"Li W, Huang T, Xu S, Che B, Yu Y, Zhang W, et al. Molecular mechanism of tanshinone against prostate cancer. Molecules. 2022b;5594. https:\/\/doi.org\/10.3390\/molecules27175594.","journal-title":"Molecules"},{"key":"10091_CR20","doi-asserted-by":"publisher","unstructured":"Linxweiler J, Hajili T, K\u00f6rbel C, Berchem C, Zeuschner P, M\u00fcller A, et al. Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model [Internet]. Sci Rep. Springer Science and Business Media LLC; 2020 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1038\/s41598-020-69424-x","DOI":"10.1038\/s41598-020-69424-x"},{"key":"10091_CR21","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.22010","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhu X, Xu C, Min F, Yu G, Chen C. Ulinastatin ameliorates the malignant progression of prostate cancer cells by blocking the RhoA\/ROCK\/NLRP3 pathway. Drug Dev Res. 2022. https:\/\/doi.org\/10.1002\/ddr.22010.","journal-title":"Drug Dev Res"},{"key":"10091_CR22","doi-asserted-by":"publisher","unstructured":"Mosquera MJ, Kim S, Bareja R, Fang Z, Cai S, Pan H, et al. Extracellular Matrix in Synthetic Hydrogel\u2010Based Prostate Cancer Organoids Regulate Therapeutic Response to EZH2 and DRD2 Inhibitors [Internet]. Advanced Materials. Wiley; 2021 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1002\/adma.202100096","DOI":"10.1002\/adma.202100096"},{"key":"10091_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2017.02.002","author":"JJ Nunes","year":"2017","unstructured":"Nunes JJ, Pandey SK, Yadav A, Goel S, Ateeq B. Targeting NF-kappa B signaling by artesunate restores sensitivity of castrate-resistant prostate cancer cells to antiandrogens. Neoplasia. 2017. https:\/\/doi.org\/10.1016\/j.neo.2017.02.002.","journal-title":"Neoplasia"},{"key":"10091_CR24","doi-asserted-by":"publisher","unstructured":"Peng H, Chen L, Deng Y, Liao X, Yang Y. Ginsenoside Rh2 mitigates myocardial damage in acute myocardial infarction by regulating pyroptosis of cardiomyocytes [Internet]. Clinical and Experimental Hypertension. Informa UK Limited; 2023 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1080\/10641963.2023.2229536","DOI":"10.1080\/10641963.2023.2229536"},{"key":"10091_CR25","doi-asserted-by":"publisher","DOI":"10.1126\/science.abf8403","author":"N Pernigoni","year":"2021","unstructured":"Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Cal\u00ec B, et al. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. Science. 2021. https:\/\/doi.org\/10.1126\/science.abf8403.","journal-title":"Science"},{"key":"10091_CR26","doi-asserted-by":"publisher","unstructured":"Prabhakar AT, James CD, Youssef AH, Hossain RA, Hill RD, Bristol ML, et al. A human papillomavirus 16 E2-TopBP1 dependent SIRT1-p300 acetylation switch regulates mitotic viral and human protein levels and activates the DNA damage response [Internet]. mBio. American Society for Microbiology; 2024 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1128\/mbio.00676-24","DOI":"10.1128\/mbio.00676-24"},{"key":"10091_CR27","doi-asserted-by":"publisher","DOI":"10.1667\/rade-20-00139.1","author":"H Qin","year":"2021","unstructured":"Qin H, Zhang H, Zhang S, Zhu S, Wang H, Radiation Research Society. Protective effect of Sirt1 against radiation-induced damage. Radiat Res. 2021. https:\/\/doi.org\/10.1667\/rade-20-00139.1.","journal-title":"Radiat Res"},{"key":"10091_CR28","doi-asserted-by":"publisher","unstructured":"Song C, Yuan Y, Zhou J, He Z, Hu Y, Xie Y, et al. Network Pharmacology-Based Prediction and Verification of Ginsenoside Rh2-Induced Apoptosis of A549 Cells via the PI3K\/Akt Pathway [Internet]. Front. Pharmacol. Frontiers Media SA; 2022 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.3389\/fphar.2022.878937","DOI":"10.3389\/fphar.2022.878937"},{"key":"10091_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/molecules29061320","volume":"29","author":"WH Talib","year":"2024","unstructured":"Talib WH, Baban MM, Azzam AO, Issa JJ, Ali AY, AlSuwais AKh, et al. Allicin and cancer hallmarks. Molecules. 2024;29:1320. https:\/\/doi.org\/10.3390\/molecules29061320.","journal-title":"Molecules"},{"key":"10091_CR30","doi-asserted-by":"publisher","unstructured":"Tian S, Lei Z, Gong Z, Sun Z, Xu D, Piao M. Clinical implication of prognostic and predictive biomarkers for castration-resistant prostate cancer: a systematic review [Internet]. Cancer Cell Int. Springer Science and Business Media LLC; 2020 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1186\/s12935-020-01508-0","DOI":"10.1186\/s12935-020-01508-0"},{"key":"10091_CR31","doi-asserted-by":"publisher","unstructured":"Tong-Lin Wu T, Tong Y-C, Chen I-H, Niu H-S, Li Y, Cheng J-T. Induction of apoptosis in prostate cancer by ginsenoside Rh2 [Internet]. Oncotarget. Impact Journals, LLC; 2018 [cited 2025 Jul 29]. p. 11109\u201318. Available from: https:\/\/doi.org\/10.18632\/oncotarget.24326","DOI":"10.18632\/oncotarget.24326"},{"key":"10091_CR32","doi-asserted-by":"publisher","DOI":"10.2147\/idr.s393654","author":"C Wang","year":"2022","unstructured":"Wang C, Li S, Shen Y, Li Y, Chen M, Wang Y, et al. Mechanisms of Panax ginseng on treating sepsis by RNA-seq technology. IDR. 2022. https:\/\/doi.org\/10.2147\/idr.s393654.","journal-title":"IDR"},{"key":"10091_CR33","doi-asserted-by":"publisher","unstructured":"Wang W, Wang H, Rayburn ER, Zhao Y, Hill DL, Zhang R. 20(S)-25-methoxyl-dammarane-3\u03b2, 12\u03b2, 20-triol, a novel natural product for prostate cancer therapy: activity in vitro and in vivo and mechanisms of action [Internet]. Br J Cancer. Springer Science and Business Media LLC; 2008 [cited 2025 Jul 29]. p. 792\u2013802. Available from: https:\/\/doi.org\/10.1038\/sj.bjc.6604227","DOI":"10.1038\/sj.bjc.6604227"},{"issue":"7","key":"10091_CR34","first-page":"4493","volume":"14","author":"Y Wen","year":"2022","unstructured":"Wen Y, Huang H, Huang B, Liao X. HSA-miR-34a-5p regulates the SIRT1\/TP53 axis in prostate cancer. Am J Transl Res. 2022;14(7):4493.","journal-title":"Am J Transl Res"},{"key":"10091_CR35","doi-asserted-by":"publisher","unstructured":"Xie L, Li C, Wang C, Wu Z, Wang C, Chen C, et al. Aspirin\u2010Mediated Acetylation of SIRT1 Maintains Intestinal Immune Homeostasis [Internet]. Advanced Science. Wiley; 2024 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1002\/advs.202306378","DOI":"10.1002\/advs.202306378"},{"key":"10091_CR36","doi-asserted-by":"publisher","unstructured":"Yamada Y, Beltran H. Clinical and Biological Features of Neuroendocrine Prostate Cancer [Internet]. Curr Oncol Rep. Springer Science and Business Media LLC; 2021 [cited 2025 Jul 29]. Available from: https:\/\/doi.org\/10.1007\/s11912-020-01003-9","DOI":"10.1007\/s11912-020-01003-9"}],"container-title":["Cell Biology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-025-10091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10565-025-10091-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10565-025-10091-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T08:34:00Z","timestamp":1760517240000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10565-025-10091-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,15]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10091"],"URL":"https:\/\/doi.org\/10.1007\/s10565-025-10091-x","relation":{},"ISSN":["1573-6822"],"issn-type":[{"value":"1573-6822","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,15]]},"assertion":[{"value":"11 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal studies were conducted in accordance with the guidelines outlined in the \"Guide for the Care and Use of Laboratory Animals\". This study strictly adhered to these guidelines to ensure animal welfare and ethical compliance. The experimental protocol was reviewed and approved by the Animal Ethics Committee of Huashan Hospital, Fudan University (Approval Number: 22YF1404300).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial number"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"139"}}